Paschen, Annette

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,039

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation

Immune Cell Function and InteractionImmunotherapy and Immune Responses

Cited by 347

A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma

Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 199

Genetic evolution of T-cell resistance in the course of melanoma progression

Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., et al. (2014) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 171

Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

López-Cobo, S., Pieper, N., Campos-Silva, C., García-Cuesta, E. M., Reyburn, H. T., Paschen, A., & Valés-Gómez, M. (2018) · OncoImmunology

Immune Cell Function and InteractionCancer Immunotherapy and Biomarkers

Cited by 71